Neurodegenerative Brain Diseases, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium; Institute Born-Bunge, Antwerp, Belgium.
Neurodegenerative Brain Diseases, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium; Institute Born-Bunge, Antwerp, Belgium.
Neurobiol Dis. 2021 Aug;156:105421. doi: 10.1016/j.nbd.2021.105421. Epub 2021 Jun 9.
Neurodegenerative disorders like frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are pathologically characterized by toxic protein deposition in the cytoplasm or nucleus of affected neurons and glial cells. Many of these aggregated proteins belong to the class of RNA binding proteins (RBP), and, when mutated, account for a significant subset of familial ALS and FTD cases. Here, we present first genetic evidence for the RBP gene RBM45 in the FTD-ALS spectrum. RBM45 shows many parallels with other FTD-ALS associated genes and proteins. Multiple lines of evidence have demonstrated that RBM45 is an RBP that, upon mutation, redistributes to the cytoplasm where it co-aggregates with other RBPs into cytoplasmic stress granules (SG), evolving to persistent toxic TDP-43 immunoreactive inclusions. Exome sequencing in two affected first cousins of a heavily affected early-onset dementia family listed a number of candidate genes. The gene with the highest pathogenicity score was the RBP gene RBM45. In the family, the RBM45 Arg183* nonsense mutation co-segregated in both affected cousins. Validation in an unrelated patient (n = 548) / control (n = 734) cohort identified an additional RBM45 Arg183* carrier with bvFTD on a shared 4 Mb haplotype. Transcript and protein expression analysis demonstrated loss of nuclear RBM45, suggestive of a loss-of-function disease mechanism. Further, two more ultra-rare VUS, one in the nuclear localization signal (NLS, p.Lys456Arg) in an ALS patient and one in the intrinsically disordered homo-oligomer assembly (HOA) domain (p.Arg314Gln) in a patient with nfvPPA were detected. Our findings suggest that the pathomechanisms linking RBM45 with FTD and ALS may be related to its loss of nuclear function as a mediator of mRNA splicing, cytoplasmic retention or its inability to form homo-oligomers, leading to aggregate formation with trapping of other RBPs including TDP-43, which may accumulate into persisted TDP-43 inclusions.
神经退行性疾病,如额颞叶痴呆(FTD)和肌萎缩侧索硬化症(ALS),在病理上以细胞质或细胞核中有毒蛋白质的沉积为特征,受影响的神经元和神经胶质细胞。这些聚集的蛋白质中有许多属于 RNA 结合蛋白(RBP),当发生突变时,占家族性 ALS 和 FTD 病例的很大一部分。在这里,我们首次提供了 FTD-ALS 谱中 RBP 基因 RBM45 的遗传证据。RBM45 与其他 FTD-ALS 相关基因和蛋白有许多相似之处。多条证据表明,RBM45 是一种 RBP,突变后会重新分布到细胞质中,在细胞质中与其他 RBPs 共同聚集形成细胞质应激颗粒(SG),发展为持续存在的有毒 TDP-43 免疫反应性包含物。对一个受严重影响的早发性痴呆家族的两个受影响的表亲进行外显子组测序,列出了一些候选基因。具有最高致病性评分的基因是 RBP 基因 RBM45。在该家族中,RBM45 Arg183无意义突变与两个受影响的表亲共分离。在一个无关的患者(n=548)/对照(n=734)队列中的验证确定了另一个携带 RBM45 Arg183的患者,该患者在共享的 4 Mb 单倍型上患有 bvFTD。转录和蛋白质表达分析表明核 RBM45 的丢失,提示存在功能丧失的疾病机制。此外,还检测到另外两个超罕见的 VUS,一个位于核定位信号(NLS,p.Lys456Arg)中,位于 ALS 患者中,另一个位于内在无序的同型寡聚体组装(HOA)域中(p.Arg314Gln)在患有 nfvPPA 的患者中。我们的研究结果表明,RBM45 与 FTD 和 ALS 相关的发病机制可能与其作为 mRNA 剪接的核功能丧失、细胞质保留或其不能形成同型寡聚物的能力有关,导致与其他 RBPs 包括 TDP-43 的聚集形成,可能会积累到持续存在的 TDP-43 包含物中。